[go: up one dir, main page]

AR077901A1 - Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer - Google Patents

Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer

Info

Publication number
AR077901A1
AR077901A1 ARP100103069A ARP100103069A AR077901A1 AR 077901 A1 AR077901 A1 AR 077901A1 AR P100103069 A ARP100103069 A AR P100103069A AR P100103069 A ARP100103069 A AR P100103069A AR 077901 A1 AR077901 A1 AR 077901A1
Authority
AR
Argentina
Prior art keywords
diagnosis
antibody
cmet
prognosis
oncogenic
Prior art date
Application number
ARP100103069A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR077901A1 publication Critical patent/AR077901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente se relaciona con el campo del pronostico y/o diagnosis de una enfermedad proliferativa en un paciente. Más específicamente, se relaciona con un anticuerpo con capacidad para unirse específicamente al receptor cMet humano, (receptor del HGF factor de crecimiento de hepatocitos), como así también las secuencias de aminoácidos y ácidos nucleicos que codifican este anticuerpo. Comprende asimismo el uso de dicho anticuerpo y los correspondientes procesos para la deteccion y diagnostico de trastornos patologicos oncogénicos hiperproliferativos asociados a la expresion de cMet. En ciertas realizaciones, los trastornos son trastornos oncogénicos asociados a la expresion incrementada del polipéptido cMet con respecto a lo normal o cualquier otra patología asociada a la sobreexpresion de cMet. Comprende, por ultimo, productos y/o composiciones o kits que comprenden por lo menos dicho anticuerpo para el pronostico o diagnostico de ciertos cánceres.
ARP100103069A 2009-08-21 2010-08-23 Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer AR077901A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23586409P 2009-08-21 2009-08-21
EP09305777A EP2287197A1 (en) 2009-08-21 2009-08-21 Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US34800510P 2010-05-25 2010-05-25

Publications (1)

Publication Number Publication Date
AR077901A1 true AR077901A1 (es) 2011-09-28

Family

ID=41571045

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103069A AR077901A1 (es) 2009-08-21 2010-08-23 Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer

Country Status (19)

Country Link
US (2) US8673302B2 (es)
EP (2) EP2287197A1 (es)
JP (1) JP5951486B2 (es)
KR (1) KR20120051734A (es)
CN (1) CN102639564B (es)
AR (1) AR077901A1 (es)
AU (1) AU2010284944B2 (es)
BR (1) BR112012003759A2 (es)
CA (1) CA2769427C (es)
ES (1) ES2692522T3 (es)
IL (1) IL218202A (es)
IN (1) IN2012DN01322A (es)
MX (1) MX2012002139A (es)
NZ (2) NZ700437A (es)
RU (1) RU2582265C2 (es)
SG (1) SG178339A1 (es)
TW (1) TW201111781A (es)
WO (1) WO2011020925A1 (es)
ZA (1) ZA201202076B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
KR101444837B1 (ko) * 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
WO2013043715A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2783217B1 (en) * 2011-11-21 2019-04-24 Taivex Therapeutics Corporation Biomarkers for cancers responsive to modulators of hec1 activity
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
ES2641444T3 (es) * 2012-05-09 2017-11-10 Eli Lilly And Company Procedimiento de preparación de cloruros de 4-[[(benzoil)amino]sulfonil]benzoílo y preparación de acilsulfamoilbenzamidas
CA2877573A1 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015032695A1 (en) * 2013-09-09 2015-03-12 Ventana Medical Systems, Inc. Scoring method for mesothelin protein expression
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
KR20160137599A (ko) 2014-03-24 2016-11-30 제넨테크, 인크. C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
WO2016124568A1 (en) * 2015-02-03 2016-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-rho gtpase conformational single domain antibodies and uses thereof
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016149535A1 (en) * 2015-03-18 2016-09-22 Seattle Genetics, Inc. Cd48 antibodies and conjugates thereof
WO2017135791A1 (en) * 2016-02-05 2017-08-10 Viromed Co., Ltd. Anti-c-met antibodies and uses thereof
EP3804765A1 (en) 2016-05-17 2021-04-14 AbbVie Biotherapeutics Inc. Anti-cmet antibody drug conjugates and methods for their use
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
RU2735918C2 (ru) * 2018-06-07 2020-11-10 Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" Набор реагентов для выявления маркера эпителиальных карцином
EP3816186A4 (en) * 2018-06-29 2022-04-06 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. PD-L1 BINDING POLYPEPTIDES AND USE THEREOF
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
US20220252603A1 (en) * 2019-06-06 2022-08-11 Apollomics Inc. (Hangzhou) Method for treating cancer patients using c-met inhibitor
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
JP7510518B2 (ja) 2020-09-01 2024-07-03 レメゲン シーオー．，エルティーディー． 抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用
IL300952A (en) * 2020-09-08 2023-04-01 Ideaya Biosciences Inc Drug combination and tumor treatment
CN119343377A (zh) * 2022-06-09 2025-01-21 圣塔安娜生物股份有限公司 靶向c-Kit和/或siglec的抗体及其用途
CN120019076A (zh) 2022-07-30 2025-05-16 松树治疗公司 用于靶向溶酶体降解的组合物及其使用方法
WO2025036355A1 (zh) * 2023-08-14 2025-02-20 明慧医药（杭州）有限公司 抗c-MET纳米抗体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
AU2002357388A1 (en) * 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7964365B2 (en) * 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer

Also Published As

Publication number Publication date
AU2010284944B2 (en) 2016-01-28
US8673302B2 (en) 2014-03-18
WO2011020925A1 (en) 2011-02-24
IL218202A0 (en) 2012-04-30
SG178339A1 (en) 2012-03-29
RU2012109004A (ru) 2013-09-27
IN2012DN01322A (es) 2015-06-05
AU2010284944A1 (en) 2012-03-08
BR112012003759A2 (pt) 2017-07-11
JP2013502213A (ja) 2013-01-24
ZA201202076B (en) 2012-11-28
EP2467402A1 (en) 2012-06-27
TW201111781A (en) 2011-04-01
ES2692522T3 (es) 2018-12-04
IL218202A (en) 2017-07-31
RU2582265C2 (ru) 2016-04-20
EP2467402B1 (en) 2018-08-01
JP5951486B2 (ja) 2016-07-13
NZ598194A (en) 2015-05-29
US20140295452A1 (en) 2014-10-02
US20120149031A1 (en) 2012-06-14
CA2769427A1 (en) 2011-02-24
CN102639564A (zh) 2012-08-15
EP2287197A1 (en) 2011-02-23
CN102639564B (zh) 2015-01-07
MX2012002139A (es) 2012-03-07
KR20120051734A (ko) 2012-05-22
CA2769427C (en) 2020-03-10
NZ700437A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
AR077901A1 (es) Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer
AR081696A1 (es) Anticuerpo para el diagnostico y/o pronostico de cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
MX358517B (es) Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
IL201778A0 (en) Peptide imaging agents
MX366965B (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
NI201200014A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
GB0718967D0 (en) Peptide imaging agents
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
EA201490825A8 (ru) Tdp-43-специфически связывающие молекулы
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
BR112016005802A2 (pt) conjugados de clorotoxina e métodos de seu uso
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
EA201291044A1 (ru) Слитый белок robo1-fc и его применение в лечении опухолей
AR063493A1 (es) Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido

Legal Events

Date Code Title Description
FA Abandonment or withdrawal